Introduction {#S1}
============

Currently, treatment for susceptible tuberculosis involves the administration of several drugs over a 6 month period, which can be extended for up to 18 months for multidrug-resistant tuberculosis ([@B50]). The main problems in achieving optimal results during tuberculosis treatment are the length of treatment and the occurrence of adverse effects that favor poor compliance, treatment failure and resistance ([@B42]). In addition, tuberculosis is associated with various pulmonary complications such as fibrosis, bronchiectasis, and long-term chronic obstructive pulmonary disease, even when a cure is achieved ([@B46]). Therefore, it is necessary to develop new drugs that shorten the treatment duration, improve the immune response, or reduce lung damage caused by infection.

Recently, it has been proposed that drugs that modify the host immune response to infection rather than drugs directly acting against the pathogen may be more effective for treatment. This type of drug treatment is known as host-directed therapy. The use of drugs that reduce excessive inflammation, prevent tissue damage, or improve treatment efficacy has been proposed to eliminate infection by modulating the host immune response. Using host-directed therapies as an adjunct to standard anti-TB treatment could also reduce the infection duration and eventually lead to decreased relapse rates ([@B24]). These types of drugs, including rapamycin, metformin, valproic acid, ibuprofen, and statins, have also been shown to affect the growth of mycobacteria in infected cells in *in vitro* studies ([@B38]; [@B52]).

The primary effect of statins is a reduction in plasma cholesterol levels. Their mechanism of action is based on inhibition of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid, a precursor of cholesterol ([@B26]). In addition to these effects, various other immunomodulatory effects have been reported that have been associated with better results in the treatment of several infectious diseases ([@B44]). Some of these effects involve modification of the expression levels of receptors involved in antigen presentation, immune cell activation, and the regulation of cytokine production ([@B10]).

*In vitro* studies of *Mycobacterium tuberculosis* infection have shown that statins reduce the growth of *M. tuberculosis* ([@B30]). In particular, simvastatin increased the bactericidal effects of first-line drugs that are often used to treat tuberculosis (i.e., isoniazid, rifampicin, and pyrazinamide) in an experimental BALB/c mice model both *in vitro* and *in vivo* ([@B18]).

Although there is evidence that statins may contribute to the containment of *M. tuberculosis* infection, their effects on cells involved in the immune response have not been previously described. The investigation of such effects is important, as pleiotropic outcomes have been shown to affect the ability of the immune response to control infection. Therefore, the aim of this study was to evaluate the effect of simvastatin on peripheral blood mononuclear cells (PBMCs) in terms of phenotype expression, function and control of *M. tuberculosis* infection, tested with *M. tuberculosis* H37Rv using an *in vitro* experimental model.

Materials and Methods {#S2}
=====================

PBMCs were obtained from leukocyte concentrates from 10 healthy blood donors (7 men and 3 women) with a mean age of 30.9 years (±5.22 SD) who visited the blood bank in a third-level care institution in Mexico City. The inclusion criteria were age over 18 years, no history of using immunosuppressive drugs, no active tuberculosis infection, and no use of antimicrobial drugs during the last 7 days before the sample was taken. All donors signed written informed consent. The study was approved by the Institutional Review Board (Comité de Ética en Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán) (REF. 1628).

Mononuclear Cell Isolation {#S2.SS1}
--------------------------

PBMCs were separated from a 20 mL sample of leukocyte concentrate via a Ficoll-Hypaque (Sigma-Aldrich, Oakville, Canada) density gradient ([@B4]). The cells were counted using a TC20 automated cell counter (Bio-Rad, Hercules, CA, United States), and the cell viability was simultaneously evaluated using trypan blue staining. The cell pellet was resuspended at a concentration of 2 × 10^6^ cells/mL in RPMI-1640 medium (Gibco, Grand Island, NY, United States) supplemented with 10% fetal bovine serum and 2 mM glutamine without antibiotics.

Preparation of *Mycobacterium tuberculosis* Cultures {#S2.SS2}
----------------------------------------------------

*M. tuberculosis* H37Rv was cultured in Middlebrook 7H9 + OADC medium (Becton Dickinson, Sparks, MA, United States) supplemented with 0.2% glycerol and 0.05% Tween 80. The cultures were incubated at 37°C until they reached logarithmic phase (∼21 days). The bacterial mass was harvested via centrifugation, and 2 mL aliquots were prepared and stored at −70°C in cryovials containing Middlebrook medium.

For the immunofluorescence experiments, *M. tuberculosis* H37Rv was transformed with pCherry8 (provided by Addgene, Cambridge, MA, United States) via electroporation ([@B16]); this plasmid expresses the reporter fluorescent protein mCherry from the Psmyc promoter ([@B6]). Next, the bacteria were cultured in Middlebrook 7H9 medium supplemented with OADC, 0.05% Tween-80 (Sigma-Aldrich), and hygromycin B (Roche Life Science, Indianapolis, IN, United States) at 37°C until they reached logarithmic phase (∼21 days). The bacterial mass was harvested via centrifugation, and 2 mL aliquots were prepared and stored at −70°C in cryovials containing Middlebrook medium.

Preparation of the Simvastatin Stock Solution {#S2.SS3}
---------------------------------------------

Inactive simvastatin (lactone) (Sigma-Aldrich, Oakville, Canada) and either its active form or the beta-hydroxylated metabolite (β-hydroxy-acid or simvastatin acid) were used. Simvastatin or simvastatin acid concentrations ranging from 0.1 to 20 μM were tested. A 25 mM stock solution was prepared by dissolving 1.04 mg of simvastatin in a 30:70 (v/v) solution of dimethyl sulfoxide (DMSO) and absolute ethanol (EtOH). Subsequently, the stock solution was divided into two 500 μL aliquots. One aliquot was diluted in PBS (pH 7.4) to a concentration of 500 μM and sterilized via filtration through a 0.22 μm filter (Millipore, Carrigtwohill, Ireland); the other aliquot was activated via alkaline hydrolysis with 0.1 M NaOH at 50°C for 2 h, diluted in PBS (pH 7.4) to a concentration of 500 μM and then sterilized via filtration through a 0.22 μm filter ([@B33]; [@B15]).

Treatment of *Mycobacterium tuberculosis* With Simvastatin and Direct Determination of the Number of Colony Forming Units (CFUs) via Plate Dilution {#S2.SS4}
---------------------------------------------------------------------------------------------------------------------------------------------------

From the logarithmic phase culture of *M. tuberculosis* H37Rv, 2 mL was withdrawn and adjusted to a concentration equivalent to the 0.5 McFarland Standard (approximately 1.5 × 10^8^ CFU/ml) in Middlebrook 7H9 medium (Becton Dickinson) using a nephelometer (Biomerieux Vitek, Hach Co, Loveland, United States). Serial dilutions were made until a concentration of 1.5 × 10^4^ CFU/mL was obtained. In a 24-well plate, 1 mL of 1.5 × 10^4^ CFU/mL *M. tuberculosis* H37Rv was added in triplicate. Some of the samples were cultured in the presence of simvastatin or simvastatin acid, while others were cultured without treatment or with the vehicle (0.024% DMSO and 0.056% EtOH in PBS). Simvastatin and simvastatin acid were added at the following concentrations: 0.1, 0.5, 1, 2, 5, 10, 15, and 20 μM. The plates were incubated at 37°C in a 7.5% CO~2~ atmosphere for 96 h ([@B37]). To quantify the mycobacterial growth, serial dilutions were made. Ten microliter aliquots were obtained and inoculated onto Middlebrook 7H10 agar plates (Becton Dickinson) followed by incubation at 37°C in a 7.5% CO~2~ atmosphere. The plates were examined, and the CFU/mL counts were collected on days 7, 14, and 21.

Infection of Mononuclear Cells With *Mycobacterium tuberculosis* {#S2.SS5}
----------------------------------------------------------------

One vial of *M. tuberculosis* H37Rv logarithmic phase culture was thawed and centrifuged at 13,300 rpm for 10 min, and the supernatant was decanted. Subsequently, the bacterial pellet was resuspended in 1 mL of RPMI (Gibco, Carlsbad, CA, United States) supplemented with 10% fetal bovine serum, 1% non-essential amino acids (Gibco), 1% essential amino acids (Gibco), and 1% sodium pyruvate (Sigma) and then transferred to a 14 mL tube. To remove any bacterial lumps or aggregates, the suspension was passed through a 5 μm syringe filter (Millipore), and the single-cell count was obtained using a Petroff-Hausser chamber (Hausser Scientific, Horsham, PA, United States). The cells were infected at multiplicities of infection (MOIs) of 0.01, 0.1, and 1 (number of bacteria/cell).

Infection of Mononuclear Cells With *Mycobacterium tuberculosis* and Treatment With Simvastatin {#S2.SS6}
-----------------------------------------------------------------------------------------------

In each well of a 24-well plate, 1 mL of RPMI containing 2 × 10^6^ PBMC/mL was exposed to 1, 5, or 20 μM simvastatin or simvastatin acid. In addition, PBMCs treated with the vehicle (0.024% DMSO and 0.056% EtOH in PBS) and cells under basal conditions (cells cultured in RPMI) were also included. A total of 2 × 10^6^ PBMC/mL were infected at MOIs of 0.01, 0.1, and 1. The PBMCs were incubated in RPMI-1640 medium (Gibco) supplemented with 10% fetal bovine serum, 2 mM glutamine, 1% v/v non-essential amino acids, 1% v/v essential amino acids (Gibco), and 1% v/v sodium pyruvate (Sigma) at 37°C in a 5% CO~2~ atmosphere. Twenty-four hours after infection, the cell viability was evaluated via trypan blue staining using a TC-20 instrument (Bio-Rad). After 96 h, the PBMCs were lysed in sterile distilled water for 3 min. Subsequently, serial dilutions were made, and 10 μL aliquots were inoculated onto Middlebrook 7H10 agar plates (Becton Dickinson) to determine the CFU/mL.

Immunophenotyping of Infected and Uninfected Mononuclear Cells Treated With Simvastatin {#S2.SS7}
---------------------------------------------------------------------------------------

The PBMC concentration was adjusted to 2 × 10^6^ cells/mL, and 5 mL (1 × 10^7^ cells) of this suspension was seeded in RPMI medium in 25 mm^2^ cell culture flasks. The following conditions were used: (1) 1 μM simvastatin acid (SA1μM); (2) 20 μM simvastatin acid (SA20 μM); (3) 1 μM simvastatin (S1 μM); and (4) 20 μM simvastatin (S20 μM). The controls were cells exposed to the vehicle (0.024% DMSO and 0.056% EtOH in PBS) (No Tx) and cells exposed to phorbol myristate acetate (25 ng/mL) and ionomycin (1 μg/mL) (PMA + I). All flasks were incubated at 37°C in a 5% CO~2~ atmosphere. After 24 h, the phenotypes and activation status of the helper T cells (CD4+), cytotoxic T cells (CD8+), NKT cells (CD3+ Vα24- J18+), NK cells (CD3- CD16 CD56+), and monocytes (CD14+) were evaluated.

Other culture flasks were incubated under the previously described conditions for 24 h, and the cells were subsequently infected with *M. tuberculosis* H37Rv at an MOI of 0.1 (IFX SA1 μM; IFX SA20 μM; IFX S1 μM; IFX 20 μM; IFX (cells exposed to the vehicle and infected); IFX PMA + I). Twenty four hours post-infection, the phenotypes and activation status of the helper T cells (CD4+), cytotoxic T cells (CD8+), NKT cells (CD3+ Vα24- J18+), NK cells (CD3- CD16 CD56+), and monocytes (CD14+) were evaluated. The antibody panel was: anti-CD25-FITC, anti-CD69-PE, anti-CD14-PE, anti-CD3-PercP, anti-CD8-PeCy7, anti-CD4-APC, anti-CD16-APC Cy7, anti-CD56-APC Cy7, anti-CD80-PercP, anti-CD86-PeCy7, anti-CD16-APC Cy7, and anti-Vα24-J18-APC (Biolegend, San Diego, CA, United States). The FcγR receptors were blocked prior to staining with 10% human AB serum. The samples were measured using a FACSCanto II flow cytometer (BD Biosciences), and the data were analyzed using FlowJo software (Tree Star Inc., Ashland, OR, United States). The cut-off point was established using the fluorescence minus one (FMO) strategy. Single-cell selection was based on cell size and granularity (FSC vs. SSC). First, the CD3- and CD3+ cells were selected. From the CD3- cells, the CD16+ and CD56+ cells were selected to identify the NK cells. From the CD3+ cells, those expressing CD4 or CD8 were selected. In turn, the CD3+ CD4+ Vα24-Jα18+ cells and CD3+ CD8+ Vα24- Jα18+ cells were sub-selected ([Supplementary Figure 1A](#SM1){ref-type="supplementary-material"}).

To identify the monocytes, cells were again selected based on size and granularity. Subsequently, the CD14+ cells were selected, and from these, the CD14+ monocytes (classical) and CD14+ CD16+ monocytes (non-classical) were selected. The expression of co-stimulatory molecules (CD80 and C86) in both the classical and non-classical monocytes was also examined. The mean fluorescence intensity (MFI), an indicator of the receptor density per cell, was evaluated to determine the C80 and CD86 expression levels in the monocytes ([Supplementary Figure 1B](#SM1){ref-type="supplementary-material"}).

Functional Analysis of the Effects of Simvastatin on Cytotoxic T Cells, NK Cells, and NKT Cells via Degranulation Kinetics {#S2.SS8}
--------------------------------------------------------------------------------------------------------------------------

The degranulation capacity of CD8+ T, NKT, and NK cells was evaluated by examining the degranulation kinetics using flow cytometry as previously described ([@B48]). Briefly, the PBMC concentration was adjusted to 2 × 10^6^ cells/mL; from this suspension, 5 mL (1 × 10^7^ cells) was seeded in RPMI medium contained in 25 mm^2^ cell culture flasks that were incubated under the six previously described conditions. Three microliters of previously titrated anti-CD107a-PE antibody was added to each culture. After 1 h of incubation, 2 μM monensin was added (Biolegend). Aliquots containing 1 × 10^6^ cells were withdrawn after 2 and 5 h of incubation, and the cells were labeled with anti-perforin-FITC, anti-CD107a-PE, anti-CD3-PercP, anti-CD8-PeCy7, anti-CD4 APC, anti-CD16 APC Cy7, anti-CD56 APC Cy7, and anti-Vα24-J18 APC (Biolegend) antibodies. The degranulation capacity was also evaluated in cells cultured under the previously described conditions and infected with *M. tuberculosis* H37Rv at an MOI of 0.1. Three microliters of anti-CD107a-PE antibody was added to each culture. After 1 h of incubation, 2 μM monensin was added (Biolegend). Aliquots containing 1 × 10^6^ cells were withdrawn after 2 and 5 h of incubation, and the cells were labeled with anti-perforin-FITC, anti-CD107a-PE, anti-CD3-PercP, anti-CD8-PeCy7, anti-CD4 APC, anti-CD16 APC Cy7, anti-CD56 APC Cy7, and anti-Vα24-J18 APC (Biolegend) antibodies. All samples were measured in a FACSCanto II flow cytometer (BD Biosciences), and the data were analyzed using FlowJo software (Tree Star Inc., Ashland, OR, United States). The cut-off point was established using the FMO strategy.

Effects of Simvastatin on Cytokine Production by *Mycobacterium tuberculosis*-Infected and Uninfected Mononuclear Cells {#S2.SS9}
-----------------------------------------------------------------------------------------------------------------------

The cytokine levels were measured in supernatant from cultures of *M. tuberculosis* H37Rv-infected (MOI of 0.1) and uninfected cells treated as previously described. Twenty four hours post-treatment or post-infection, the supernatants were collected and stored in cryotubes at −70°C until analysis. To determine the cytokine levels, a Cytokine Bead Array (CBA) kit (Becton Dickinson, Biosciences) was used according to the manufacturer's instructions. The levels of IFN-γ, TNFα, IL-1β, IL12p70, IL-17A, and IL-10 were quantified. The samples were measured using a FACSCanto II flow cytometer (BD Biosciences).

Evaluation of the Effects of Simvastatin on Apoptosis and Autophagy in *Mycobacterium tuberculosis*-Infected Mononuclear Cells {#S2.SS10}
------------------------------------------------------------------------------------------------------------------------------

Five milliliters of RPMI containing 1 × 10^7^ cells was seeded in 25 mm^2^ flasks and cultured under the following conditions (those which showed the greatest effects in the previous tests): (1) 20 μM simvastatin acid (SA 20 μM); (2) untreated cells exposed to the vehicle (0.024% DMSO and 0.056% EtOH in PBS); (3) cells infected at an MOI of 0.1; and (4) cells infected at an MOI of 0.1 and treated with 20 μM simvastatin acid. The cells were incubated at 37°C in a 5% CO~2~ atmosphere for 24 h. Subsequently, the induction of apoptosis and autophagy in these cells was evaluated.

To evaluate the induction of apoptosis, the CV-Caspase 3 and 7 detection kit (Enzo Life Sciences, NY, United States) was used. This kit contains CR(DEVD)2, a substrate that fluoresces after caspase 3 and 7 activation. PBMCs treated with 100 μM etoposide for 8 h were used as a positive control.

To measure autophagy, the CYTO-ID^®^ 2.0 autophagy detection kit (Enzo Life Sciences) was used. This kit stains autophagic compartments while ensuring minimal staining of lysosomes ([@B19]). PBMCs treated with 500 nM rapamycin for 8 h were used as a positive control.

To distinguish between the induction of autophagy in helper T cells, cytotoxic T cells, NKT cells, NK cells, and monocytes, the following monoclonal antibodies were used: anti-CD14 PE, anti-CD3 coupled to PercP, anti CD8-PeCy7, anti-CD4 APC, anti-CD16 APC-Cy7, anti-CD56 APC-Cy7, anti-CD16 APC-Cy7, and anti-Vα24-J18 APC (Biolegend). The FMO strategy was used to establish the cut-off points. For each cell subtype, the percentages of cells stained with CYTO-ID^®^ were compared between the different treatments (rapamycin; 20 μM simvastatin; infection with *M. tuberculosis* H37Rv; and infection with *M. tuberculosis* H37Rv and 20 μM simvastatin).

The same strategy \[comparison of the percentages of cells stained with CR (DEVD)2\] was used to evaluate the effects of simvastatin on the induction of apoptosis. The samples were measured using a FACSCanto II flow cytometer (BD Biosciences) ([Supplementary Figure 2](#SM1){ref-type="supplementary-material"}).

Additionally, microphotographs were obtained from an experiment in which 2 mL of PBMCs (2 × 10^6^ cells/mL) were seeded in RPMI medium in a 24-well plate and then subjected to the following conditions: (1) infection with the *M. tuberculosis* H37Rv-mCherry strain at an MOI of 1, and (2) infection with the *M. tuberculosis* H37Rv-mCherry strain at an MOI of 1 and treatment with 20 μM simvastatin acid. The cells were incubated at 37°C in a 5% CO~2~ atmosphere for 24 h. Subsequently, the cells were stained using the CYTO-ID^®^ 2.0 kit (Enzo Life Sciences) and with Hoechst 33342 (FABRICANTE) according to the manufacturer's instructions. The cells were fixed in 4% paraformaldehyde. To adhere the cells to the coverslip, the PBMCs were centrifuged at 1800 rpm for 3 min in a Cytopro^®^ Cytocentrifuge Series 2 centrifuge (Puteaux, France). The cells were observed using confocal fluorescence microscopy with an LSM 710-DUOX inverted system (Carl Zeiss AG, Germany), and images were obtained using ZEN 2009 software (version 6.0, SP2; Carl Zeiss AG, Germany).

Statistical Analysis {#S2.SS11}
--------------------

To compare two groups of non-parametric data, the Mann--Whitney *U*-test was used. For comparisons among four groups, the Kruskal--Wallis test was used. The data were analyzed using GraphPad Prism v6.0 software (La Jolla, CA, United States). A *p* ≤ 0.05 was considered to denote statistical significance. The results are expressed as the mean ± standard error.

Results {#S3}
=======

Direct Effects of Simvastatin on *Mycobacterium tuberculosis* Growth {#S3.SS1}
--------------------------------------------------------------------

Different simvastatin concentrations (0.1--20 μM) were tested. The analysis of the growth kinetics showed that simvastatin, regardless of its activation state or concentration, had no direct bactericidal effects (*p* \> 0.05; [Figure 1](#F1){ref-type="fig"}).

![Direct effects of simvastatin on *Mycobacterium tuberculosis* growth expressed in colony forming units (CFUs). In a 24-well plate, 1.5 × 10^4^ CFU/mL *M. tuberculosis* H37Rv was added in triplicate and cultured in the presence of simvastatin acid (SA, red dots), simvastatin (S, purple squares), vehicle (0.024% DMSO and 0.056% EtOH in PBS, black triangles), and without any treatment/inoculum (blue triangles). The plates were incubated at 37°C in a 7.5% CO~2~ atmosphere for 24, 48, 72, or 96 h. Serial dilutions were made on Middlebrook 7H10 agar to determine the CFU/mL. Colonies were counted on days 7, 14, and 21. The simvastatin concentrations are indicated at the top of each graph, *n* = 5 (*p* \> 0.05).](fmicb-10-02097-g001){#F1}

Effects of Simvastatin on *Mycobacterium tuberculosis* Growth in Infected Mononuclear Cells {#S3.SS2}
-------------------------------------------------------------------------------------------

The optimal MOI for the infection of PBMCs resulted on 0.1 because an MOI of 1 induced cell death and a lower MOI induced very few phenotypic changes in the PBMCs ([Supplementary Figure 3](#SM1){ref-type="supplementary-material"}). It was observed that PBMCs that were infected and incubated for 96 h and treated with 1 μM simvastatin or 1 μM simvastatin acid, exhibited reduced bacterial loads compared to those of the control cells and/or those treated with the vehicle (reduction from 3.75 × 10^6^ to 6.88 × 10^5^ CFU/mL; *p* \< 0.05). The decrease in bacterial load was even greater at a concentration of 20 μM (reduction from 1.92 × 10^7^ CFU/mL to 5.35 × 10^6^ CFU/mL; *p* \< 0.001; [Figure 2](#F2){ref-type="fig"}). The effects of the two forms of simvastatin were dose-dependent. Based on these results, it was decided that concentrations of 1 and 20 μM would be used in the subsequent experiments.

![Effects of simvastatin on the growth of *Mycobacterium tuberculosis* in peripheral blood mononuclear cells. In a 24-well plate, 2 × 10^6^ PBMCs/mL were seeded and exposed to 1, 5, and 20 μM simvastatin and simvastatin acid. PBMCs treated with the vehicle (0.024% DMSO and 0.056% EtOH in PBS) and cells under basal conditions (cells cultured in RPMI) were included as controls. The cells were infected at an MOI of 0.1. The cells were incubated at 37°C in a 5% CO~2~ atmosphere. After 96 h, the cells were lysed, and serial dilutions were made. The serial dilutions were inoculated in triplicate onto Middlebrook 7H10 agar plates for CFU/mL determination, *n* = 10 (Kruskal--Wallis, ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01).](fmicb-10-02097-g002){#F2}

Effects of Simvastatin on Phenotypes of Uninfected Mononuclear Cells {#S3.SS3}
--------------------------------------------------------------------

The effect of simvastatin on the cell viability of PBMCs was evaluated using trypan blue staining and the automated cell counter TC-20. No cytotoxic effect was observed, even using pharmacological concentrations ([Supplementary Figure 4](#SM1){ref-type="supplementary-material"}).

Treatment with 20 μM simvastatin increased the percentages of CD4+ NKT cells (1.63% ± 0.70 vs. 0.57% ± 0.3780; *p* \< 0.05) and CD8+ NKT cells (1.69% ± 0.522 vs. 0.52% ± 0.38; *p* \< 0.05) ([Figures 3A,B](#F3){ref-type="fig"}; left side). Representative dot plots for the effect of simvastatin on NKTs are shown in [Supplementary Figure 5](#SM1){ref-type="supplementary-material"}. Simvastatin treatment did not affect the percentages of NK ([Figure 3C](#F3){ref-type="fig"}). Treatment with simvastatin did not increase the percentage of classical and non-classical monocytes ([Figures 3D,G](#F3){ref-type="fig"}; left side). However, in classical and non-classical monocytes, simvastatin treatment increased the expression levels of the co-stimulatory molecules CD80 (CD14+ CD80+, 60.28% ± 12.98 vs. 23.71% ± 11.44, p \< 0.05; CD14+ CD16+ CD80+, 30.91% ± 8.33 vs. 15.69 ± 5.68; [Figures 3E,H](#F3){ref-type="fig"}; left side) and CD86 (CD14+ CD86+, 55.64% ± 8.44 vs. 19.49% ± 3.9; CD14+ CD16+ CD86+, 64.45% ± 9.29 vs. 34.73% ± 14.52; [Figures 3F,I](#F3){ref-type="fig"}; left side). Representative dot plots for the effect of simvastatin on the expression of CD80 and CD86 in monocytes are shown in [Supplementary Figure 6](#SM1){ref-type="supplementary-material"}.

![Effects of simvastatin on the phenotypes of infected and uninfected peripheral mononuclear cells. PBMCs were incubated under the following conditions: 1 μM simvastatin acid (SA1 μM), 20 μM simvastatin acid (SA20 μM), 1 μM simvastatin (S1 μM), and 20 μM simvastatin (S20 μM). The control cells were untreated cells exposed to vehicle (0.024% DMSO and 0.056% EtOH in PBS) (No Tx), or cells treated with phorbol myristate acetate (25 ng/mL) plus ionomycin (1 μg/mL). Other culture flasks were incubated under the previously described conditions for 24 h, and the cells were subsequently infected with *M. tuberculosis* H37Rv at an MOI of 0.1 (IFX SA1 μM; IFX SA20 μM; IFX S1 μM; IFX 20 M m; IFX (cells exposed to the vehicle and infected); IFX PMA + I). After 24 h, the phenotypes of the NKT cells **(A,B)**, NK cells **(C)**, and monocytes **(D,G)** were evaluated. The effects of simvastatin on the expression levels of CD80 **(E,H)** and CD86 **(F,I--K)** in monocytes are also shown, *n* = 10 (Kruskal--Wallis, ^∗^*p* \< 0.05, ^∗^*p* \< 0.01).](fmicb-10-02097-g003){#F3}

Simvastatin treatment did not affect the percentages or activation status of CD4+ T and CD8+ T cells based on the measurement of the expression levels of CD25 and/or CD69 ([Supplementary Figure 7](#SM1){ref-type="supplementary-material"}).

Effects of Simvastatin on Phenotypes of Mononuclear Cells Infected With *Mycobacterium tuberculosis* {#S3.SS4}
----------------------------------------------------------------------------------------------------

Infected PBMCs exposed to 20 μM simvastatin showed an increase in the percentage of CD4+ NKT cells (1.7 ± 0.57 vs. 0.79 ± 0.33; *p* \< 0.05) and CD8+ NKT cells (1.79 ± 0.31 vs. 0.48 ± 0.28; *p* \< 0.05). [Figures 3A,B](#F3){ref-type="fig"}; right side. Representative dot plots for the effect of simvastatin on NKTs are shown in [Supplementary Figure 5](#SM1){ref-type="supplementary-material"}.

Classical and non-classical monocytes showed no changes ([Figures 3D,G](#F3){ref-type="fig"}; right side). However, the expression levels of CD80 and CD86 were increased in classical monocytes (CD14+ CD80+, 72.15% ± 5.6 vs. 57.31% ± 7.13; CD14+ CD86+, 95.92% ± 2.9 vs. 87.14% ± 3.14) ([Figures 3E,F](#F3){ref-type="fig"}; right side). In non-classical monocytes, simvastatin had no effect on the expression levels of CD80 and CD86 ([Figures 3H,I](#F3){ref-type="fig"}; right side). However, upon analyzing the CD80 and CD86 receptor densities, it was observed that simvastatin treatment increased the MFIs of CD80 (5142 ± 1482 vs. 2103 ± 379.6; *p* \< 0.05) and CD86 (3108 ± 745.6 vs. 1476 ± 456.5; *p* \< 0.05; [Figures 3J,K](#F3){ref-type="fig"}) in these cells. Interestingly the simvastatin effect becomes more consistent when cells are infected. Representative dot plots for the effect of simvastatin on the expression of CD80 and CD86 in infected monocytes are shown in [Supplementary Figure 6](#SM1){ref-type="supplementary-material"}.

Infected lymphocytes showed increased expression levels of the activation markers CD25 and CD69, as expected, and exposure to simvastatin did not induce additional changes ([Supplementary Figure 8](#SM1){ref-type="supplementary-material"}).

Effects of Simvastatin on Degranulation of CD8+ T Cells, NK Cells, and NKT Cells {#S3.SS5}
--------------------------------------------------------------------------------

Simvastatin treatment did not affect the degranulation of CD8+ T, NK, and NKT cells ([Supplementary Figure 9](#SM1){ref-type="supplementary-material"}). In addition, it was observed that when PBMCs were infected with *M. tuberculosis* (exposed and non-exposed to simvastatin) the CD107a expression increased and perforin expression decreased in CD8+ T cells, NK cells, and NKT cells after 5 h. This observation indicated that infection, *per se*, causes degranulation in these cells and that simvastatin did not induce additional changes.

Effects of Simvastatin on Cytokine Production in Infected and Uninfected Mononuclear Cells {#S3.SS6}
------------------------------------------------------------------------------------------

Simvastatin treatment did not result in significant changes in the secretion of IFN-γ, TNF-α, IL-1β, IL12-p70, IL-17A, and IL-10 in uninfected PBMCs ([Figure 4A](#F4){ref-type="fig"}). However, in infected simvastatin-treated PBMCs, the levels of the pro-inflammatory cytokines IL-12-p70 (0.9 ± 1.79 pg/mL vs. 10.46 ± 7.48 pg/mL; *p* \< 0.05) and IL-1β (14.7 ± 8.0 vs. 1676 ± 624.7; *p* \< 0.05) were higher compared to their levels in untreated PBMCs. Simvastatin treatment also promoted IL-10 secretion in infected PBMCs (4.2 ± 1.911 vs. 63.2 ± 22.78; *p* \< 0.05, see [Figure 4B](#F4){ref-type="fig"}). No significant changes were observed in the production of IFN-γ, TNF-α, and IL-17A in infected PBMCs.

![Effects of simvastatin on cytokine production in infected and uninfected peripheral mononuclear cells. **(A)** Effects of simvastatin on cytokine production in non-infected PBMCs. Cytokine production was measured in the supernatant of PBMCs incubated for 24 h with 1 μM simvastatin acid (SA1 μM), 20 μM simvastatin acid (SA20 μM), 1 μM simvastatin (S1 μM), and 20 μM simvastatin (S20 μM). The control cells were untreated cells exposed to vehicle (0.024% DMSO and 0.056% EtOH in PBS) (No Tx), or cells treated with phorbol myristate acetate (25 ng/mL) plus ionomycin (1 μg/mL). **(B)** Effects of simvastatin on cytokine production in infected PBMCs. The culture boxes were incubated in the previously described conditions for 24 h and subsequently, infected with *M. tuberculosis* H37Rv at an MOI of 0.1. At 24 h post-infection, the supernatant was collected, and cytokine production was measured, *n* = 10 (Kruskal--Wallis, ^∗^*p* \< 0.05, ^∗^*p* \< 0.01).](fmicb-10-02097-g004){#F4}

Evaluation of the Effects of Simvastatin on Apoptosis and Autophagy in Infected and Uninfected Mononuclear Cells {#S3.SS7}
----------------------------------------------------------------------------------------------------------------

In uninfected PBMCs treated with 20 μM simvastatin, an increase in the percentage of CR (DEVD)2-labeled PBMCs was observed compared with that in the untreated PBMCs, however, this difference was not statistically significant. Furthermore, an increase in the induction of apoptosis was observed in infected and treated PBMCs compared with infected non-treated PBMCs (37.3% ± 4.7 vs. 55.1% ± 5.8; *p* \< 0.05).

Using flow cytometry, lymphocytes, monocytes and NK and NKT cells were examined to determine whether apoptosis was induced in all cell types or only in specific cell types. [Figure 5](#F5){ref-type="fig"} shows that simvastatin did not induce activation of the caspase pathway in NK and NKT cells, however, the percentage of CR (DEVD)2-stained lymphocytes was increased, indicating an increase in the induction of apoptosis (uninfected lymphocytes: 26.84% ± 7.86; uninfected and treated lymphocytes: 42.76% ± 4.56). In infected and treated PBMCs, the induction of apoptosis was shown to be greater in lymphocytes (50.6% ± 9.10 vs. 67.3% ± 9.2; *p* \< 0.05) and monocytes (56.3% ± 13.2 vs. 83.6% ± 2.6; *p* \< 0.05; [Figure 5](#F5){ref-type="fig"}).

![Effects of simvastatin on apoptosis in infected with *Mycobacterium tuberculosis* and uninfected peripheral mononuclear cells. The induction of apoptosis was evaluated in PBMCs treated for 24 h under the following conditions: 20 μM simvastatin acid (SA20 μM), untreated cells exposed to vehicle (0.024% DMSO and 0.056% EtOH in PBS) (No Tx), cells infected at an MOI of 0.1 (IFX), and cells infected at an MOI of 0.1 and treated with 20 μM simvastatin acid (IFX SA 20 μM). PBMCs treated with 100 μM etoposide for 8 h were used as a positive control for the evaluation of apoptosis. **(A)** Percentage of PBMCs positive for CR(DEVD)2; **(B)** percentage of lymphocytes positive for CR(DEVD)2; **(C)** percentage of monocytes positive for CR(DEVD)2; **(D)** percentage of NK cells positive for CR(DEVD)2; **(E)** percentage of NKT cells positive for CR(DEVD)2, *n* = 10 (Kruskal--Wallis, ^∗^*p* \< 0.05, ^∗^*p* \< 0.01).](fmicb-10-02097-g005){#F5}

Uninfected and treated PBMCs exhibited an increase in the induction of autophagy (27.1% ± 4.5 vs. 37.6% ± 5.6; *p* \< 0.05), and this effect was consistent in infected and treated PBMCs (37.36% ± 4.77 vs. 55.18% ± 5.8; *p* \< 0.05; [Figures 6A](#F6){ref-type="fig"}, [7](#F7){ref-type="fig"}). Microphotographs show intact mycobacteria inside in some infected PBMCs (red). The induction of autophagy was also observed independent of infection (green). In infected and treated PBMCs, sequestration of red stain within autophagosomes (green) and loss of *M. tuberculosis* integrity were observed ([Figure 7](#F7){ref-type="fig"}).

![Effects of simvastatin on autophagy in infected and uninfected peripheral mononuclear cells. The induction of autophagy was evaluated in PBMCs treated for 24 h under the following conditions: 20 μM simvastatin acid (SA20 μM), untreated cells exposed to vehicle (0.024% DMSO and 0.056% EtOH in PBS) (No Tx), cells infected at an MOI of 0.1 (IFX), and cells infected at an MOI of 0.1 and treated with 20 μM simvastatin acid (IFX SA 20 μM). PBMCs treated with 500 nM rapamycin for 8 h were used as a positive control for the evaluation of autophagy. **(A)** Percentage of PBMCs positive for CYTO-ID; **(B)** percentage of lymphocytes positive for CYTO-ID; **(C)** percentage of monocytes positive for CYTO-ID; **(D)** percentage of NK cells positive for CYTO-ID; **(E)** percentage of NKT cells positive for CYTO-ID, *n* = 10 (Kruskal--Wallis, ^∗^*p* \< 0.05, ^∗^*p* \< 0.01).](fmicb-10-02097-g006){#F6}

![Induction of autophagy in peripheral blood mononuclear cells infected with *Mycobacterium tuberculosis* H37Rv-mCherry and treated with simvastatin. A total of 2 × 10^6^ PBMCs was seeded in a 24-well plate and cultured under the following conditions: (1) PBMCs infected at an MOI of 1 with *M. tuberculosis* strain H37Rv-mCherry, and (2) cells infected at an MOI of 1 with *M. tuberculosis* strain H37Rv-mCherry and treated with 20 μM simvastatin acid. Uninfected no treated cells were included as controls. The cells were incubated at 37°C in a 5% CO~2~ atmosphere for 24 h and then stained with Cyto-ID and Hoechst 33342 for detection of autophagosomes (green) and visualization of nuclei (blue), respectively. The stained cells were analyzed using confocal microscopy. (A) Intact mycobacteria were observed inside some infected PBMCs (red). The induction of autophagy was also observed independent of infection (green). (B) Sequestration of red stain within autophagosomes (green) and loss of the integrity of mycobacteria were observed in infected and treated PBMCs. Scale bar, 5 μm.](fmicb-10-02097-g007){#F7}

Likewise, analyses of the results for each subpopulations ([Figures 6B--E](#F6){ref-type="fig"}) showed that the induction of autophagy was greater in monocytes, both in uninfected and treated cells (22.65% ± 2.4 vs. 36.38% ± 4.72%) and in infected and treated cells (56.33% ± 13.27 vs. 83.63% ± 2.6%; *p* \< 0.05; [Figure 6C](#F6){ref-type="fig"}).

Discussion {#S4}
==========

In this study, we described the effects of simvastatin on PBMCs in general and in terms of specific cell subtypes. We demonstrate that simvastatin and its metabolically active form (simvastatin acid) favors bacillus elimination via activation of several cellular mechanisms, including increased percentages of NKT cells within cultures, increased expression of co-stimulatory molecules on monocytes, higher secretion of the IL-1β and IL-12p70 cytokines, and activation of apoptosis and autophagy in monocytes. All of these effects, together, promoted improved *M. tuberculosis* elimination ([Figure 8](#F8){ref-type="fig"}).

![Simvastatin enhances the immune response against *Mycobacterium tuberculosis* in an *in vitro* model. Simvastatin decreased the growth of *M. tuberculosis* in PBMCs, increased the proportion of NKT cells in culture, increased the expression levels increased the proportion of NKT cells in culture, increased the expression of co-stimulatory molecules in monocytes, promoted the secretion of the cytokines IL-1β and IL-12p70, and activated apoptosis and autophagy in monocytes, resulting in a significant reduction in bacterial load. We also observed an increase in IL-10 production.](fmicb-10-02097-g008){#F8}

Simvastatin also favors IL-10 secretion and activated lymphocyte apoptosis, both of which are relevant phenomena that could inhibit adequate infection control, however, they could also mitigate the damage caused by excessive inflammation.

Regarding the possible bactericidal effects of simvastatin against *M. tuberculosis*, [@B39] tested concentrations up to 320 μM and did not observe any inhibitory effects. In contrast, [@B32] observed an inhibitory effect at an MIC of 100 μg/mL (238.91 μM). In this study, we tested simvastatin concentrations ranging from 0.1 to 20 μM, which included the concentrations typically used in *in vitro* studies, and we did not detect any microbicidal effects. However, infected PBMCs treated with simvastatin exhibited a lower bacterial load.

Studies of the inhibitory effects of simvastatin on the growth of mycobacteria have been performed in macrophages ([@B30]) and macrophage-like cell lines (THP-1, J774) ([@B23]; [@B39]). In this study, we evaluated the effects of simvastatin on the growth of *M. tuberculosis* H37Rv in PBMCs. The results showed simvastatin significantly reduced the growth of *M. tuberculosis* in infected PBMCs in a dose-dependent manner.

We also analyzed the effects of simvastatin on the cellular subtypes that were present in the experimental model. It was shown that simvastatin increased the percentages of CD4+ and CD8+ NKT cells. [@B25] reported that patients with hypercholesterolemia treated with simvastatin for at least 6 months showed increases in the number of peripheral blood NKT cells. On the other hand, several studies have reported a decrease in the number of NKT cells in subjects with active tuberculosis ([@B40]), and *in vitro* experiments have demonstrated the ability of NKT cells to kill *M. tuberculosis*-infected macrophages ([@B34]). Therefore, an increase in the percentages of CD4+ and CD8+ NKT cells is proposed to favor the protective immune response against mycobacteria.

We also observed that treatment with simvastatin at a pharmacological concentration (20 μM) increased the expression levels of the co-stimulatory molecules CD80 and CD86 in both infected and uninfected classical and non-classical monocytes. [@B1] reported that simvastatin did not alter the expression levels of co-stimulatory molecules in dendritic cells; Atilla et al. observed that simvastatin treatment reduced the expression of CD83 and CD86 in dendritic cells derived from monocytes ([@B51]). [@B17] reported an increase in CD86 expression in simvastatin-treated CD14+ CD56+ cells. [@B5] reported that in *S. aureus*-infected macrophages, simvastatin treatment did not alter the expression levels of the co-stimulatory CD80 and CD86 proteins. Under the experimental conditions used in this study, *M. tuberculosis*-infected PBMCs treated with simvastatin exhibited increased CD80 and CD86 expression in classical and non-classical monocytes. Consistently, Bhatt et al. reported that B7.1 and B7.2 (the murine homologs of CD80 and CD86) knockout mice are more susceptible to *M. tuberculosis* infection and that the B7 receptor signaling pathway is critical for long-term containment of infection within lung granulomas ([@B3]). In another study, cells recovered from induced sputum from patients with tuberculosis and controls were analyzed, and it was observed that cells from the infected patients had lower expression levels of co-stimulatory molecules (CD80 and CD86) ([@B13]). Decreased expression of these molecules, which are involved in antigen presentation and T-cell activation, in patients could lead to decreased T-cell recognition during *M. tuberculosis* infection. Therefore, a simvastatim-induced increase in the expression levels of these molecules, similar to that observed in this study, could favor T-cell recognition.

Cytokines are key for the initiation, maintenance, and modulation of the immune response against *M. tuberculosis*. In this study, we observed that simvastatin treatment increased IL- 1β and IL12p70 production in infected cells. The IL-1β cytokine is a key mediator of inflammation and plays an important role in host resistance against *M. tuberculosis* infection. Krishnan et al. reported that IL-1β knockout mice were more susceptible to *M. tuberculosis* infection and exhibited a greater bacterial load in the lungs and higher mortality at the beginning of the infection ([@B22]). Likewise, interleukin-12p70 (a heterodimer of the p35 and p40 subunits) induces bactericidal and cytolytic activity, increases the proliferation of macrophages, promotes IFN-γ production by NK cells, and plays a central role in polarization during the differentiation of T helper type 1 lymphocytes (Th1) during *M. tuberculosis* infection ([@B45]; [@B21]). On the other hand, *M. tuberculosis* inhibits IL-12p40 production in macrophages to evade the immune system ([@B9]); therefore, increased IL-1β and IL-12p70 production is proposed as another mechanism by which simvastatin favors the inhibition of *M. tuberculosis* growth in infected cells.

Our results show that simvastatin-treated infected PBMCs produced more IL-10. It has been observed that IL-10 limits the Th1 responses against *M. tuberculosis* infection ([@B31]). However, a balanced immune response is very important in restricting the growth of mycobacteria without causing excessive tissue damage, as half of treated patients have permanent damage due to excessive inflammation caused by infection ([@B47]). Despite the increase in IL-10 production observed in our study, the CFU/mL counts demonstrated that simvastatin treatment favors the inhibition of *M. tuberculosis* growth in infected PBMCs. Thus, an increase in the production of this cytokine could inhibit excessive inflammation and reduce infection-induced damage.

Previous studies have reported that simvastatin has pro-apoptotic effects in cancerous cells and that it plays a role in the immune response against *M. tuberculosis* ([@B20]). Consequently, we evaluated the effects of simvastatin on apoptosis in infected PBMCs. Our results showed that simvastatin induces apoptosis in PBMCs and does so primarily in macrophages and lymphocytes. Simvastatin-induced apoptosis in macrophages favors more effective elimination of the bacillus, while necrosis favors its dissemination ([@B14]). However, apoptosis in lymphocytes could be unfavorable for the control of the infection ([@B8]). Several studies have shown that the effectiveness of protective responses against *M. tuberculosis* infection depends mainly on its quality, as reflected in the ability of T cells to perform multiple functions, rather than on its magnitude ([@B29]). On the other hand, [@B12] reported that statin therapy shortens the duration of anti-tuberculosis treatment in mice; therefore, it is necessary to study the impact of the induction of apoptosis in lymphocytes in more detail and to determine the appropriate time to start treatment with statins in this experimental model.

[@B30] reported that simvastatin promotes autophagy in *M. tuberculosis*-infected macrophages, however, its effect on other cell types and its possible involvement in the immune response against *M. tuberculosis* have not yet been analyzed. Likewise, our results show that the induction of autophagy occurs preferentially in monocytes, favoring the elimination of the bacillus via the formation of autophagosomes. The induction of autophagy by simvastatin seems to be critical, as this mechanism contributes to the elimination of intracellular microorganisms, such as *M. tuberculosis*; furthermore, autophagy controls inflammation and prevents tissue damage in animal models ([@B11]; [@B28]).

With respect to the mechanism by which statins affect immune cells, it is known that when statins inhibit mevalonate synthesis, they also inhibit the production of other isoprenoid molecules, such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate. These molecules serve as lipid labels for the post-translational modification of several proteins, including G protein gamma subunits and small GTP-binding proteins, such as Ras, Rho, Rab, Rac, Ral, or Rap ([@B27]). This last component (prenylation inhibition) has been proposed as the mechanism by which statins modulate the immune response. This study shows the effects of simvastatin on different cell types of the human immune system that enhance the elimination of *M. tuberculosis*, however, the effect is greater with the active metabolite, simvastatin acid. This outcome was expected because simvastatin is a lactone prodrug that inhibits HMG-CoA reductase after it is hydrolyzed into its active form *in vivo* ([@B36]). Although the liver is the main organ that metabolizes statins, mononuclear cells express CYP3A and can also metabolize them ([@B43]).

This study has some limitations inherent to *in vitro* studies; for example, mononuclear cells from only 10 subjects (a small sample size) were included in the study, and the cells were obtained from healthy subjects and treated and infected outside of their "normal environment." Therefore, it is necessary to conduct clinical studies to evaluate whether these beneficial effects are observed *in vivo* and to evaluate the therapeutic potential of statins as an adjuvant therapy for tuberculosis treatment. In this regard, [@B41] conducted a retrospective study that included 102,424 statin users and 202,718 subjects matched by age and sex. The two cohorts were monitored to detect the incidence of cases with active tuberculosis. They concluded that the use of statins was an independent protective factor for the development of tuberculosis ([@B41]).

When considering the possible drug interactions of statins with current tuberculosis treatment, it is known that rifampicin decreases the simvastatin serum levels because it induces its metabolism, and the combination of isoniazid and simvastatin may increase the risk of myopathy and rhabdomyolysis because inhibits its metabolism ([@B35]; [@B49]). Therefore, additional preclinical studies are needed to identify the optimal dosage with first-line drugs.

Regarding the drug interactions of antiretrovirals with statins, it has been reported that several antiretrovirals inhibit the metabolism of statins and, therefore, may increase the risk of muscle damage (rhabdomyolysis) ([@B7]). However, [@B2] reviewed clinical studies of statins in HIV-infected patients and concluded that statins used at the recommended therapeutic dose have a relatively low risk of adverse reactions and may even confer a favorable anti-inflammatory profile in this population. Regarding the use of statins as a possible adjuvant in anti-tuberculosis treatment in HIV patients, drug interactions represent a challenge; therefore, it is necessary to conduct carefully designed clinical studies that consider factors such as the type of statins used, their dose in combination therapies, and the duration of treatment, among others.

This study is the first to evaluate the effects of simvastatin on different subpopulations of PBMCs. These results are of great importance since the immune system involves complex interactions between diverse cell types in which the balance between the activation of pro-inflammatory and anti-inflammatory mechanisms is crucial to containing the infection while causing the least possible damage. Here, we have demonstrated that simvastatin exerted three different effects that favor the immune response against *M. tuberculosis* (increased the proportion of NKT cells in culture, increased the expression of co-stimulatory molecules in monocytes, and promoted the secretion of the cytokines IL-1β and IL-12p70) and activated two mechanisms that control cell death and promote *M. tuberculosis* killing (autophagy and apoptosis). These results provide new insights into the immune correlates that how simvastatin reduce mycobacterial load in PBMCs and endorses statins as potential candidates for host-directed therapy. This study not only provides an overview of the effects of simvastatin on PBMCs, it also suggests the possibility of future studies to define the roles of anti-inflammatory mechanisms induced by statins in the treatment of *M. tuberculosis* infections and to determine the most appropriate time to start treatment with these drugs. It will be necessary to conduct in vivo studies to determine whether statin treatment effectively prevents tissue damage resulting from *M. tuberculosis* infection.
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